News
NHS England agreed to reimburse Vertex's newest cystic fibrosis medicine. Meanwhile, Merck advanced a once-monthly PrEP pill ...
3d
Pharmaceutical Technology on MSNVertex and NHS England agree reimbursement for AlyftrekVertex Pharmaceuticals has announced a reimbursement agreement with NHS England for its cystic fibrosis (CF) medicine, ...
Vertex Pharmaceuticals’ triple combination cystic fibrosis (CF) therapy has been recommended by the National Institute for ...
NHS patients in England with cystic fibrosis will be among the first in Europe to access a new treatment for their condition, ...
Reimbursement authority NICE has backed routine NHS use of Vertex's once-daily triple therapy Alyftrek ...
Latest studies show Us pharma giant Vertex's new CF wonder pill Alyftrek has shown better results than their currently ...
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of Goldman Sachs’ top healthcare stock picks. On July 1, the ...
Prof David Sheppard, Professor of Physiology, University of Bristol, said: ...
A once-a-day pill health experts are calling 'life-changing' will be offered to hundreds of people living with cystic ...
16d
Pharmaceutical Technology on MSNVertex wins European approval for Alyftrek, bolstering cystic fibrosis strongholdWith its blockbuster Trikafta set to lose patent protection within the decade, Vertex is strengthening its cystic fibrosis portfolio.
Vertex Pharmaceuticals said on Tuesday its next-generation cystic fibrosis treatment has won European Union approval for a ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results